ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma

Author(s):
Ascierto, P.A.; Arenberger, P.; Atkinson, V.G.; Hansson, J.; Kapiteijn, E.; Loquai, C.; Negrier, S.; Shaw, H.M.; Tarhini, A.; Walker, J.; Geib, J.; Rahimian, S.; Swann, S.; Diab, A.
Published
2018
Publication type
Other
Date issued
2018-10-01
Language
English
Publisher
OXFORD UNIV PRESS
hdl
1887/122837